Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Surveyor Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 150
Average round size
info
The average size of a deal this fund participated in
$120M
Portfolio companies 123
Rounds per year 9.38
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 51
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

Surveyor Capital appeared to be the VC, which was created in 2008.

Among the various public portfolio startups of the fund, we may underline Allogene Therapeutics, Annexon Biosciences, Oncorus The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Health Diagnostics, Pharmaceutical.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Surveyor Capital, startups are often financed by Skyline Ventures, SV Health Investors, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Alexandria Venture Investments, Samsara BioCapital. In the next rounds fund is usually obtained by Roche Venture Fund.

The top amount of exits for fund were in 2019. The top activity for fund was in 2019. This Surveyor Capital works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 50 - 100 millions dollars.

The overall number of key employees were 3.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Surveyor Capital:
Typical Co-investors
Surveyor Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Surveyor Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
20/20 HealthCare Partners Auburndale, Massachusetts, United States
Associated Bank Green Bay, United States, Wisconsin
Blue Horizon Ventures Switzerland, Zürich, Zurich
Changying Technology China, Guangdong Province, Maoming City
Chisage China, Ningbo, Zhejiang
Concept2Company Ventures California, Stanford, United States
DGC China, Guangdong, Shenzhen
Fubon Financial Holdings -
Gameloft Barcelona, Catalonia, Spain
J-Ventures California, Palo Alto, United States
OakStone Ventures California, Palo Alto, United States
PJT Partners New York, New York, United States
Prepaid Technologies Alabama, Birmingham, United States
Sciencons -
Specialized Types California, San Francisco, United States
Stundi Phuket, Phuket Province, Thailand
Symantec Ventures -
Virginia Tech Carilion (VTC) Innovation Fund Roanoke, United States, Virginia
Wattsense Participations -
Youdu Qiye Guanli Zixun China, Tianjin, Wuqing

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Outpace Bio

Biotechnology
Health Care
Life Science
Pharmaceutical
$144M01 Aug 2024 Seattle, Washington, United States

Scorpion Therapeutics

Biotechnology
Health Care
Life Science
$150M16 Jul 2024 Boston, Massachusetts, United States

Marea Therapeutics

$190M18 Jun 2024 San Francisco, California, United States

Aardvark Therapeutics

Health Care
Therapeutics
$85M09 May 2024 San Diego, California, United States

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$160M03 Apr 2024 Cambridge, Massachusetts, United States

ProfoundBio

Biotechnology
Therapeutics
$112M13 Feb 2024 Suzhou, Jiangsu, China

Attralus

Biopharma
Biotechnology
Health Care
Medical
$56M06 Feb 2024 San Francisco, California, United States

Sudo Biosciences

Biopharma
$116M20 Dec 2023 Menlo Park, California, United States

Avalyn Pharma

Biopharma
Biotechnology
Medical
Pharmaceutical
$175M27 Sep 2023 Seattle, Washington, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Surveyor Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 150
Average round size 120M
Rounds per year 9.38
Peak activity year 2021
Lead investments 8
Follow on index 0.17
Exits 51
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Outpace Bio

Biotechnology
Health Care
Life Science
Pharmaceutical
$144M01 Aug 2024 Seattle, Washington, United States

Scorpion Therapeutics

Biotechnology
Health Care
Life Science
$150M16 Jul 2024 Boston, Massachusetts, United States

Marea Therapeutics

$190M18 Jun 2024 San Francisco, California, United States

Aardvark Therapeutics

Health Care
Therapeutics
$85M09 May 2024 San Diego, California, United States

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$160M03 Apr 2024 Cambridge, Massachusetts, United States

ProfoundBio

Biotechnology
Therapeutics
$112M13 Feb 2024 Suzhou, Jiangsu, China

Attralus

Biopharma
Biotechnology
Health Care
Medical
$56M06 Feb 2024 San Francisco, California, United States

Sudo Biosciences

Biopharma
$116M20 Dec 2023 Menlo Park, California, United States

Avalyn Pharma

Biopharma
Biotechnology
Medical
Pharmaceutical
$175M27 Sep 2023 Seattle, Washington, United States
Crunchbase icon

Content report

The following text will be sent to our editors: